Bio Bridge Science Inc - Current report filing (8-K)
October 31 2007 - 1:57PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of
1934
Date
of
Report (Date of earliest event reported)
October
31, 2007
BIO-BRIDGE
SCIENCE, INC.
|
(Exact
name of registrant as specified in its
charter)
|
Delaware
|
|
20-1802936
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
1211
West 22nd Street, Suite 615
Oak
Brook, Illinois
|
60523
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
630-928-0869
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting
material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
This
Form 8-K and other reports filed by the Registrant from time to time with the
Securities and Exchange Commission (collectively the “Filings”) contain forward
looking statements and information that are based upon beliefs of, and
information currently available to, the Registrant’s management as well as
estimates and assumptions made by the Registrant’s management. When used in the
Filings the words “anticipate”, “believe”, “estimate”, “expect”, “future”,
“intend”, “plan” or the negative of these terms and similar expressions as they
relate to the Registrant or the Registrant’s management identify forward looking
statements. Such statements reflect the current view of the Registrant with
respect to future events and are subject to risks, uncertainties, assumptions
and other factors relating to the Registrant’s industry, operations and results
of operations and any businesses that may be acquired by the Registrant. Should
one or more of these risks or uncertainties materialize, or should the
underlying assumptions prove incorrect, actual results may differ significantly
from those anticipated, believed, estimated, expected, intended or
planned.
I
TEM
7.01
- REGULATION FD DISCLOSURE
On
October 31, 2007, the Company issued a press release announcing the execution
of
a non-binding Letter of Intent to acquire control of Lanzhou Roya Biotechnology
Co. Ltd. A copy of this press release has been filed with this Current Report
on
Form 8-K as Exhibit 99.1 and is incorporated herein by this
reference.
The
information in Item 7.01 of this report shall not be deemed "filed" for purposes
of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to
the
liabilities of that section, nor shall it be deemed incorporated by reference
in
any filing under the Securities Act of 1933 or the Securities Exchange Act
of
1934, except as expressly set forth by specific reference in such a
filing.
ITEM
9.01
Financial Statements and Exhibits.
(a)
|
Financial
statements of business acquired.
|
(b)
|
Pro
forma financial information.
|
Exhibit
Number
Description
99.1
|
Press
release issued October 31, 2007
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
|
|
|
|
|
Bio-Bridge
Science, Inc.
|
|
|
|
|
|
Date
|
October
31, 2007
|
|
|
|
|
|
|
By:
|
/s/ Kevin Lee
|
|
|
|
Name
|
Kevin Lee
|
|
|
|
Title:
|
Chief Financial Officer
|
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2023 to Jul 2024